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ABSTRACT 
Wound healing disorders affect between 3 and 6 million Americans every year.  
Treatment options are variable and often unsuccessful, resulting in amputation.   
However, one commonly used treatment option applies growth factors and 
proteins topically to the site of the wound to improve the rate of healing.  More 
recently, a positive role for the topical administration of thyroid hormone has also 
proven effective.  These findings are interesting considering the systemic role of 
thyroid hormone on the skin where in the absence of Graves’ disease, patients 
with thyrotoxicosis have thinner skin.  Questions still remain about the 
contradictory role of systemic and topical administrations of thyroid hormone, but 
research suggests that the topical application of thyroid hormone could be a 
useful therapeutic agent in patients with wound healing disorders.  
 Other than the keratin genes in keratinocytes, the molecular targets of 
thyroid hormone are unknown.  The complexity of wound healing makes it 
challenging to determine which factors are directly or indirectly affected by 
thyroid hormone, however, the integrin-β1 family could be a likely target.  The 
integrin-β1 proteins are expressed in both keratinocytes and fibroblasts and play 
an important role in fibrogenesis.  In addition, conditional knockouts for the 
 iv 
integrin-β1 gene display reduced rates of wound healing.  Therefore, the 
expression of integrin-β1 protein was analyzed by Western Blotting to determine 
whether fibroblasts dosed with thyroid hormone caused an increase in integrin-β1 
expression. 
 The experiment revealed that the expression of integrin-β1 is dependent 
on the presence of thyroid hormone.  Furthermore, integrin-β1 is expressed 
maximally at physiological concentrations of thyroid hormone.  These results 
suggest that thyroid hormone may improve wound healing by stimulating 
expression of integrin-β1 proteins.  
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INTRODUCTION 
 
 
THYROID HORMONE SYNTHESIS AND METABOLISM 
Thyroid hormone (TH) is an important regulator of energy homeostasis 
(Molina, 2009).  It is released into the systemic circulation and impacts cell 
metabolism and activity in virtually all tissues (Molina, 2009).  TH is crucial for 
normal gestational development since maternal deficiencies that deprive the 
fetus of adequate levels of TH may result in severe mental retardation and 
dwarfism (Barrett et al., 2012).  Although TH is not generally considered an 
essential endocrine hormone during adult life, deviations from normal blood 
concentrations generate undesirable and potentially severe symptoms.  
Thyroid hormone is produced in the thyroid gland.  This butterfly-shaped 
gland consists of two lobes that straddle either side of the trachea and are 
connected by a piece of tissue called the isthmus (Barrett et al., 2012).  The 
thyroid gland is one of the largest endocrine glands in the body and is highly 
vascularized.  It is made of approximately three million spherical follicles that 
consist of an outer layer of polarized epithelial cells and a protein-filled center, 
known as colloid (Barrett et al., 2012).  The colloid is composed of thyroglobulin, 
which is a large glycoprotein that serves as the building block for THs.  The 
colloid matrix is in contact with the apical side of thyroid follicular cells 
(thyrocytes) while the basolateral membrane is lined with the gland’s blood 
vessels.  The histological structure of the thyroid gland is unique and is 
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fundamental to understanding the biosynthesis, storage and secretion of thyroid 
hormone.  
 The thyroid gland synthesizes two different hormones: tri-iodothyroxine 
(T3) and tetra-iodothyroxine (T4), also known as thyroxine (Mescher, 2009).  The 
synthesis of these hormones depends on the availability of iodide, which is an 
essential nutrient and the rate-limiting step in TH synthesis (Braverman & Utiger, 
2004).  The thyroid gland ensures the iodide supply is adequate by keeping the 
thyroid iodide concentration twenty to forty times greater than the iodide 
concentration in the blood (Braverman & Utiger, 2004).  As a result, the 
movement of iodide from the blood into the thyroid follicular cells occurs against 
its electrochemical gradient through secondary active transport.  The 
transmembrane protein responsible for this transport has been identified as a 
sodium-iodide (Na+/I-) symporter (NIS) (Barrett et al., 2012).  The movement of 
sodium out of the thyroid follicular cells and down its concentration gradient is the 
driving force for iodide transport.  The sodium gradient is generated by the 
Na+/K+-adenosine triphosphate (ATP)-ase, which is also located on the 
basolateral membrane of the thyroid follicular cells.   
Upon entry into the thyroid follicular cell, iodide is subsequently 
transported into the colloid by a transporter on the apical membrane.  This 
transporter is commonly listed as Pendrin, but there are conflicting sources of 
data to this effect.  In several studies, Pendrin is shown transporting iodide 
across the apical membrane into the colloid.  Yet, individuals diagnosed with 
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Pendred syndrome, a condition characterized by mutation and dysfunction of the 
Pendrin transporter, do not necessarily display a hypothyroid phenotype.  
Knockout (KO) studies for the pendrin protein in animal models confirm this fact, 
thereby suggesting that it does not play an essential role in moving iodide across 
the apical membrane of thyroid follicular cells (Twyffels et al., 2011).  Although its 
mode of transport is still unclear, iodide moves into the follicular matrix, where 
the biosynthesis of TH begins (Braverman & Utiger, 2004).   
Once in the colloid, Iodide is oxidized to iodine near the apical side of the 
membrane.  This chemical reaction is catalyzed by thyroid peroxidase (TPO) and 
requires the presence of hydrogen peroxide (H2O2).  TPO also catalyzes a 
second reaction referred to as organification where one or two iodine molecules 
are covalently bound to selected tyrosyl resides in thyroglobulin producing 
monoiodotyrosine (MIT) or diiodotryosine (DIT) respectively (Braverman & Utiger, 
2004).  The predominant form of TH is produced in the next step by coupling two 
molecules of DIT together to form T4.  T3 is formed less frequently by coupling 
one molecule of DIT with one molecule of MIT (Friesema, Jansen, & Visser, 
2005). 
T3 and T4 are stored in the colloid until they are needed in the systemic 
circulation.  These hormones are then transported back through the follicular 
cells to reach the blood stream.  The colloid containing T3, T4, MIT, DIT and 
thyroglobulin undergoes non-selective or receptor-mediated endocytosis into the 
follicular cell (Braverman & Utiger, 2004).  The thyroglobulin-containing vesicles 
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fuse with the lysosomes in order to detach T3 and T4 from thyroglobulin for 
secretion.  In addition, DIT and MIT are metabolized by an intrathyroidal 
dehalogenase protein in order to preserve and recycle iodide for further hormone 
synthesis (Moreno et al., 2008).  T3 and T4 are then transported into the 
circulation across the basolateral membrane of the thyrocyte.  The 
monocarboxylate transporter 8 (MCT8) may facilitate the movement of THs since 
MCT8 KO mice have significantly lower T4 serum concentrations compared to 
normal mice (Di Cosmo et al., 2010).  
Although T4 is the predominant form of TH synthesized by the thyroid 
gland, T3 is more biologically active.  Therefore, the majority of T4 that is formed 
is converted to T3 by two enzymes: deiodinase type 1 (D1) and deiodinase type 
2 (D2) (Figure 1).  These intracellular enzymes are located within the thyroid 
gland and the peripheral tissues, and are responsible for producing 80% of all 
active T3 (Braverman & Utiger, 2004).  Deiodinase type 3 (D3) is a third enzyme 
that inactivates T4 by removing an iodide from the inner ring of the tyrosyl 
residue (Figure 1).  
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Figure 1: Conversion of Thyroid Hormones by Deiodinases.  T4 is converted to T3 by D1 and D2, while 
T4 is inactivated to rT3 by D3.  All three deiodinase enzymes play a role in converting T3 and rT3 into T2 
(From: Kansagra, McCudden, & Willis, 2010). 
 
THYROID HORMONE REGULATION  
 The primary regulator of TH biosynthesis and secretion is thyrotropin (also 
known as thyroid-stimulating hormone, TSH).  Thyrotropin is produced in the 
thryrotroph cells of the anterior pituitary gland.  Thyrotrophs represent less than 
ten percent of all adenohypophysial cells and are located in a cluster in the 
anteromedial portion of the anterior lobe (Gardner & Shoback, 2011a).  
Thyrotrophin is a glycoprotein with two subunits that are linked non-covalently.  It 
shares its α-subunit with pituitary luteinizing hormone (LH), pituitary follicle-
stimulating hormone (FSH), and chorionic gonadotropin (CG).  The β-subunit is 
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unique and confers binding specificity to thyrotropin so that it may directly target 
the synthesis and release of TH.   
 The receptors for TSH are located on the basolateral membrane of the 
thyroid follicular cells (Molina, 2009).  The TSH receptor is a G protein-coupled 
receptor that stimulates two intracellular pathways.  The first pathway increases 
the concentration of the intracellular messenger cyclic adenosine 
monophosphate (cAMP), which subsequently activates protein kinase A.  The 
second pathway activates phospholipase C (PLC) and ultimately increases the 
intracellular concentration of calcium.  Both intracellular pathways have a role in 
regulating the biosynthesis of TH by stimulating the transcription of thyroglobulin, 
NIS, and TPO.  Activation of the intracellular pathways also regulates iodide 
uptake, thyroglobulin iodination, iodide efflux and endocytosis of the follicular 
matrix.  In fact, there are marked histological differences in the size of the 
spherical follicles before and after thyrotropin stimulation because upon binding 
to its receptor, thyrotropin causes endocytosis and the colloid decreases in size.  
This process initiates T3 and T4 secretion from the thyroid gland by removing the 
hormones from their storage site (Gardner & Shoback, 2011b). 
 The effects of thyrotropin are regulated by second hormone called 
thyrotropin-releasing hormone (TRH).  TRH is initially synthesized as a pro-
hormone in the paraventricular nucleus of the hypothalamus and is later modified 
into its biologically active form.  TRH is then released from nerve terminals in the 
median eminence to enter the hypothalamic-pituitary portal circulation.  TRH 
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travels through the portal capillaries to reach the thyrotrophs in the anterior 
pituitary gland.  The TRH receptor is also a G protein-coupled receptor that 
activates PLC and increases intracellular calcium concentrations, ultimately, 
triggering the release of thyrotropin (Molina, 2009). 
TRH and thyrotropin form the hypothalamic-pituitary-thyroid (TRH) axis 
and are extremely important for stimulating the production and release of THs.  
As a control, TH provides direct negative feedback to both the thyrotrophs in the 
anterior pituitary and the paraventricular neurons in the hypothalamus to ensure 
that blood concentrations do not rise above a certain threshold.  T3 directly 
inhibits the transcription of the TRH gene in paraventricular neurons and 
desensitizes binding of TRH to their receptors, indirectly inhibiting transcription of 
the thyrotropin gene (Costa-e-Sousa & Hollenberg, 2012).  T3 also suppresses 
post-translational modification of the TRH pro-hormone to prevent it from 
developing into its biologically active form (Perello et al., 2006).   
 The regulation of TH stretches beyond the HPT axis.  The TRH neurons in 
the paraventricular nucleus also receive inputs from the brain.  Neurons 
containing neuropeptide Y (NPY), melanocortin stimulating hormone (α-MSH) 
and agouti-related peptide (AgRP) also stimulate TRH neurons.  The adipocyte 
hormone leptin is another peripheral input involved in regulating TRH.  Overall, 
several different inputs provide a set point for the thyroid to ensure that a 
consistent basal level of TH is produced at all times (Nillni, 2010).  
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FUNCTIONS OF THYROID HORMONE  
 TH targets virtually all tissues in the body.  It affects activities at the 
plasma membrane, the cytosol and the mitochondria; however, it primarily affects 
genomic-level activities in the nucleus.  Thus it is not surprising that thyroid 
hormone receptors (TRs) belong to the nuclear hormone receptor (NR) family 
and are located intracellularly.  There are two human genes that encode two TR 
subunits: the α-receptor gene on chromosome 17 and a β-receptor gene on 
chromosome 3.  The β-receptor gene undergoes alternative splicing giving rise to 
three TR isoforms, which bind to deoxyribonucleic acid (DNA) as homodimers, 
heterodimers and monomers (Barrett et al., 2012).   
In order for THs to exert their nuclear effects, they must first cross the 
plasma membrane (Lin et al., 2013).  Recently, a number of TH transporters 
located on the plasma membrane have been identified and characterized as 
either organic anion transporters or amino acid transporters (Friesema et al., 
2005).  These transporters may act as the rate-limiting step in TH metabolism 
and have been localized to most tissues including the kidney, liver, brain, heart, 
thyroid, eye, pituitary gland, skin and others (Hennemann et al., 1986).   
 Upon entry into the cell, T4 is usually converted by either D1 or D2 into 
T3, which binds with greater affinity than T4 to the TR.  In general, TRs operate 
as a ligand-binding transcription factor.  They bind to DNA through their DNA-
binding domain (DBD), which contains two zinc-finger motifs (Braverman & 
Utiger, 2004).  TRs bind to thyroid response elements (TRE) with high specificity 
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and affinity and often heterodimerize with another member of the NR family such 
as retinoid x receptors (RXRs) to enhance TR binding. TREs are located within 
the promoter regions of target genes and can increase or decrease the rate of 
transcription of specific proteins (Barrett et al., 2012).   
  TH function in adults is mostly metabolic.  For quite some time, scientists 
have known that excess blood concentrations of TH increase metabolic rate, and 
deficient blood concentrations of TH decrease metabolic rate (Boron & Boulpaep, 
2004).  TH also stabilizes body temperature and controls roughly 30% of resting 
energy expenditures by inducing heat production via increased ATP turnover 
(Nillni, 2010).  TH routinely affects oxygen consumption, protein, carbohydrate, 
lipid and vitamin metabolism, in addition to causing changes in gene expression 
(Braverman & Utiger, 2004).  The widespread effects of TH are commonly 
demonstrated by outlining the characteristic symptoms in cases hyperthyroidism 
and hypothyroidism, which in some instances can be very serious and result in 
life-threatening conditions. 
 The cardiac symptoms experienced by patients with thyrotoxicosis are 
extremely common.  Usually, patients have elevated heart rates, increased 
systolic blood pressure and decreased diastolic pressure, resulting in an overall 
increase in pulse pressure.  Plus, the contractility of the heart, cardiac output, 
cardiac mass and blood volume are all increased in cases of hyperthyroidism.  
Blood volume is often increased for two reasons: 1) Erythropoietin concentrations 
are elevated in response to increased oxygen consumption in the presence of 
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elevated T3 levels and 2) low diastolic pressure stimulates the renin-angiotensin-
aldosterone system causing the body to retain more fluid through the kidneys.  
Patients with thyrotoxicosis also show a 50-70% decrease in vascular resistance, 
which triggers an increase in blood flow to the muscles, skin, kidney and heart 
(Braverman & Utiger, 2004).  Research has demonstrated that the decrease in 
systemic vascular resistance may result from the direct binding of T3 to smooth 
muscle cells in the vascular wall causing vasodilation (Ojamaa, Balkman, & 
Klein, 1993).  
 The cardiac symptoms in cases of hypothyroidism are opposite from the 
symptoms described in thyrotoxicosis.  Systemic vascular resistance is reported 
to increase 50-60% above average, while cardiac output is 30-50% below 
average.  In addition, heart rate, cardiac mass, blood volume and systolic 
pressure are decreased, while diastolic pressure is increased.  In general, the 
cardiac symptoms associated with cases of hypothyroidism are less severe than 
patients with hyperthyroidism because many of the symptoms balance each 
other out.  For example, the net effect of decreased blood volume and decreased 
oxygen consumption generally results in the same oxygen extraction from the 
blood as it travels from the arteries to the veins, compared to euthyroid cases.  In 
addition, mean blood pressure is often normal because decreased cardiac output 
is balanced with an increase in vascular resistance (Braverman & Utiger, 2004).  
 The pulmonary system is not affected as extensively as the cardiovascular 
system, but elevated concentrations of T3 will increase oxygen consumption and 
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carbon dioxide production.  These changes ultimately increase the minute 
ventilation so that the body can retrieve more oxygen and dispose of greater 
quantities of carbon dioxide.  The combination of cardiac and pulmonary 
symptoms in thyrotoxic patients are magnified in individuals who exercise 
because minute ventilation and CO2 production are elevated and oxygen 
extraction is compromised in the process.  Similar to the cardiovascular system, 
the pulmonary symptoms are less severe in patients with hypothyroidism, 
although decreases in vital capacity, total lung capacity, functional residual 
capacity and expiratory reserve volume may sometimes be observed (Braverman 
& Utiger, 2004). 
 Behavioral changes may also ensue during deviations from normal TH 
concentrations.  Although complaints are variable, individuals with 
hyperthyroidism report anxiety, dysphoria, emotional liability, insomnia and 
intellectual dysfunction.  Individuals with hypothyroidism report weakness, 
fatigue, inattentiveness, loss of memory and decreased ability to perform 
everyday tasks.   
 Extreme cases of hyperthyroidism may also result in the clinical diagnosis 
of a thyrotoxic storm.  Individuals diagnosed with thyrotoxic storm may suffer 
from fever, heat intolerance, central nervous system (CNS) dysfuntion, marked 
irritability, and thyroid gland goiters.  Patients may also experience 
gastrointestinal (GI) dysfunction such as vomiting, diarrhea and nausea.  
Thyrotoxic storm is a life-threatening condition, with a high risk for comas and 
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mortality rates ranging anywhere from 10-75%.  In contrast, myxedema coma 
may occur from extremely low levels of TH and is also a very severe and life-
threatening condition.  It is often precipitated by exposure to the cold and 
lethargy often progresses to coma; patients may die from respiratory failure and 
hypothermia (Braverman & Utiger, 2004).  Overall, the effects of TH are 
widespread and physiological blood concentrations are important for normal 
organ function.  
   
WOUND HEALING 
 Wound healing is a complex process that occurs in response to tissue 
injury.  It depends on the functioning capacity and cross talk between of a variety 
of different cell types and growth factors (Braverman & Utiger, 2004).  Thus, it is 
helpful to have a general understanding of the histological and anatomical 
components of the skin to understand the process of wound healing.     
The skin is the largest organ in the body and acts as a barrier between the 
external environment and the body’s internal milieu (Boron & Boulpaep, 2004).   
The skin also plays an important role in temperature regulation, sensation, 
ultraviolet (UV) metabolism and wound repair (Goldsmith et al., 2012).  The skin 
is divided into three layers which all contribute to its functionality; these layers are 
known as the epidermis, dermis and hypodermis (Figure 2).   
The epidermis is the most superficial layer of the skin and is composed 
primarily of keratinocytes.  These cells are extremely dynamic and are organized 
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into four distinct layers: the basal layer, the spinous layer, the granular layer and 
the stratum corneum.  The basal layer is the deepest layer of the epidermis and 
is attached to a basement membrane, which separates the epidermis from the 
dermis.  The keratinocytes are derived from stem cells within basal layer and 
differentiate until they are fully matured keratinized cells of the stratum corneum 
(Goldsmith et al., 2012).  In addition to keratinocytes, melanocytes and Merkel 
cells are found in the epidermis.  Melanocytes protect the skin from UV damage 
and Merkel cells are a type of mechanoreceptors that increase skin sensitivity.    
 The dermis makes up the largest portion of the skin and is composed of 
connective tissue and a few predominant cells types.  The connective tissue 
contains collagen, proteoglycans and glycoaminoglycans (GAGs), all of which 
give the skin its characteristic elasticity, pliability and tensile strength (Goldsmith 
et al., 2012).   The resident cells of the dermis include fibroblasts, macrophages, 
and mast cells.  Cells from the immune system frequently enter and exit the 
dermis to protect the body from unwanted foreign materials. Small blood vessels, 
lymphatics and nerve bundles are also found within this layer.  The dermis and 
epidermis interact to remodel and repair the skin after injury has occurred 
(Goldsmith et al., 2012).   
 The hypodermis lies beneath the dermis and is essentially a layer of 
subcutaneous fat (Figure 2).  The adipose tissue serves as a cushion for the skin 
and is involved in inflammatory conditions.  This layer also holds the skin’s 
energy supply because it contains blood vessels, nerve bundles and lymphatic 
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vessels that are much larger in size than found in the dermis. The three layers of 
the skin are functionally integrated and each play an important role in wound 
healing.   
 
Figure 2: Layers Of The Skin.    The schematic shows the three layers of the skin. The 
epidermis is the most superficial layer, followed by the dermis and the hypodermis.  The dermis is 
the largest layer and both the dermis and hypodermis contain blood vessels, lymphatic vessels 
and nerve bundles (From: Mescher, 2009). 
Wound healing is characterized by four phases: 1) coagulation phase 2) 
inflammatory phase, 3) reepithelization phase and 4) remodeling phase.  These 
stages are somewhat artificial in nature because there is significant overlap 
between each phase; however, they are useful in explaining the intricate series 
of events that occur during wound healing.  The wound healing process is usually 
triggered by a disruption in the structural integrity of blood vessels within the skin 
(Goldsmith et al., 2012).   
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The coagulation phase is initiated immediately.  A clot is quickly produced 
to act as a temporary shield and protect the underlying tissue from the external 
environment.  The clot is composed of platelets and a mesh of cross-linked 
fibers, including fibrin, fibronectin, vitronectin and thrombospondin (Goldsmith et 
al., 2012).  A highly regulated clotting pathway involves a number of intrinsic and 
extrinsic factors that ultimately converge to cleave fibrinogen into fibrin, which 
serves as a primary component of the clot.  The tightly regulated pathway is 
required in order to prevent clot formation from occurring within the circulatory 
system under normal circumstances.  The activated platelets degranulate and 
release a variety of cytokines and growth factors including platelet-derived 
growth factor (PDGF), transforming growth factor beta 1 (TGF-β1), epidermal 
growth factor (EGF) and insulin-like growth factor 1 (IGF-1) (Martin, 1997).  The 
activation of these growth factors is triggered by the environmental conditions 
that characterize tissue injury such as low pH and hypoxia (Goldsmith et al., 
2012).  Each growth factor serves a unique function in the wound healing 
process that is outlined in Table 1.   
The inflammatory phase involves the recruitment and migration of 
leukocytes.  Inflammatory cells are attracted to the site of injury in response to 
surface changes in endothelial cells of the capillaries.  Growth factors help to 
attract these cells to the site of injury by chemotaxis.  The first inflammatory cell 
recruited is the neutrophil; this cell acts to clear out any initial bacteria or foreign 
material that may have entered at the wound site.  In addition, the neutrophil also 
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secretes tumor necrosis factor alpha (TNF-α), interleukin 1 alpha (IL-α) and 
interleukin 1 beta (IL-β); the specific functions of these growth factors are also 
outlined in Table 1 (Martin, 1997).  Within twenty-four to forty-eight hours after 
the tissue injury, monocytes are recruited from the blood stream and differentiate 
into macrophages.  At this point, they release TGF-α, heparin-binding EGF-like 
growth factor (HB-EGF), fibroblast growth factors (FGFs) 1, 2, and 4 and TGF-β1 
and –β2; their functions are outlined in Table 1 (Martin, 1997).  
The reepithelialization phase is triggered several hours after the 
coagulation and inflammatory phases have begun.  Keratinocytes migrate over 
the wound surface and produce a monolayer of cells.  The matrix 
metalloproteinase (MMP) family of proteins and the plasmin protein are 
necessary for keratinocyte migration because they facilitate their movement 
through the injured area by dissolving the fibrin clot.  Plasmin is derived from 
plasminogen, a protein derived from the clot itself, while the expression of MMPs 
are up-regulated by wound-edge keratinocytes during tissue injury (Martin, 
1997).  EGF is also a very important growth factor for keratinocyte migration.  In 
fact, studies in vitro demonstrate that EGF stimulates keratinocyte growth.  In 
addition, the topical application of biosynthetic EGF has been shown to increase 
regeneration of split-thickness wounds and partial-thickness burns in miniature 
pigs; both experiments highlight the role of EGF during reepithelialization (Brown 
et al., 1986).  The fibroblast growth factor (FGF) 7 is also involved during this 
phase as it increases keratinocyte growth and migration.   
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The remodeling phase refills the wounded area by replacing the 
extracellular matrix and closing the wound.  Connective tissue repair within the 
dermis layer of the skin is done almost exclusively by fibroblasts, as they 
synthesize the extracellular matrix by secreting collagen type 1, fibronectin and 
others components of connective tissue (Liu et al., 2010a). New fibroblasts 
migrate to the site of injury approximately three or four days after injury and are 
attracted to the site of injury by PDGR and TGF-β.  After the new connective 
tissue is deposited, TGF-β1 triggers the conversion of fibroblasts into 
myofibroblasts.  These newly differentiated cells contain alpha-smooth muscle 
actin (α-SMA) and resemble smooth muscle cells with respect to their ability to 
produce contractile forces (Desmoulière et al., 1993).  The myofibroblasts 
contract and ultimately cause wound closure.  
Throughout wound healing, new vessels are formed in a process 
described as angiogenesis in order to supply the new epithelial tissue with 
nutrients.  In fact, the tissue that is newly formed during wound healing is called 
granulation tissue because of the pink color that is derived by the invasion of 
capillaries.  FGF2 and vascular endothelial growth factor (VEGF) are released at 
the wound site to stimulate angiogenesis (Martin, 1997).  VEGF is up-regulated 
in the keratinocytes that line the edge of the wounds in response to TGF-α (Frank 
et al., 1995).  In the absence of VEGF, wound healing does not occur; therefore, 
VEGF is an essential regulator of angiogenesis in wound healing (Tang et al., 
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2013).  Interestingly, VEGF expression is markedly reduced in diabetic mice that 
have wound healing disorders (Frank et al., 1995).    
Table 1: Growth Factors Involved in Wound Healing.  These growth factors play important 
roles at various times throughout the wound healing process. 
Growth Factor Source Target Cell and Effects 
EGF Platelets Keratinocyte migration and proliferation 
FGF 
Macrophages and 
damaged 
endothelial cells 
Fibroblast proliferation and angiogenesis 
IGF-1 Platelets Endothelial cell and fibroblast proliferation 
IL-α and -β Neutrophils Stimulates the production of growth factors in macrophages, keratinocytes and fibroblasts 
PDGF 
Platelets; 
macrophages; 
keratinocytes 
Attracts macrophages and fibroblasts by 
chemotaxis; activates macrophages; fibroblast 
proliferation; matrix production 
TGF-β1 and –β2 Platelets; macrophages 
Keratinocyte migration; Attracts macrophages and 
fibroblasts by chemotaxis; stimulates fibroblasts 
for matrix production and remodeling 
TNF-α Neutrophils Keratinocyte migration and proliferation 
VEGF Keratinocytes; macrophages Angiogenesis 
 
 Overall, wound healing is a multifaceted process that requires a variety of 
cells and growth factors.  The integrated steps provide an efficient mechanism for 
tissue repair, thus minor disruptions in the wound healing process may result in 
dire consequences.  This is exemplified in diabetic patients who suffer from 
chronic wounds.  Further research is needed to improve wound repair and should 
continues to be a valuable focus within the scientific research community.  
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THYROID HORMONE ACTION ON THE SKIN 
 The actions of thyroid hormone on the skin may occur directly or indirectly.  
All three isoforms of the TRs have been identified in the skin in multiple locations 
including epidermal keratinocytes, skin fibroblasts, hair erector pili muscle cells, 
sebaceous gland cells, vascular endothelial cells, smooth muscle cells and a 
number of other skin components within the epidermal and dermal layers (Safer, 
2011).    
The effects of thyroid hormone on the skin are very apparent in cases of 
hypothyroidism.  The skin becomes cools, waxy, dry, coarse, pale, and swollen.  
In addition, the number of creases in the skin increases.  Hair becomes dry, 
coarse and brittle, and thinning of the scalp and beard usually occur (Wolff & 
Johnson, 2009).  On the contrary, the clinical observations of the skin in cases of 
hyperthyroidism are not as well documented, but are usually described as thin, 
but not atrophic.  These observations have been more difficult to attain because 
cases of hyperthyroidism are generally attributed to Graves’ disease: an 
autoimmune disease that concurrently causes skin thickening from the deposition 
of GAGs in the dermal layer (Braverman & Utiger, 2004).  Researchers have 
explored the effects of hyperthyroidism on the skin, however, studies report 
conflicting results.    
In 1967, rats were made thyrotoxic by administering T4 intraperitoneally 
and researchers observed that the skin of the rats became thinner.  At about the 
same time, a second study confirmed that thyrotoxicosis leads to increased 
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collagen metabolism (Safer et al., 2003).  However, a 1977 study contradicted 
these observations and reported decreased epidermal thickness and reduced 
rates of cell replication and anabolic activity when concentrations of T3 were 
reduced; thereby finding a positive correlation between T3 serum levels and 
epidermal thickness (Holt & Marks, 1977).  Later, in vitro studies also 
demonstrated that elevated levels of T3 increased cell replication and anabolic 
activity in the human epidermis (Holt, 1978).   
More recently, the effects of topical TH application have been 
investigated.  Safer et al. prepared a T3 cream by mixing T3 into a liposome 
vehicle.  They applied the vehicle topically to the skin in vivo and observed 
increased epidermal proliferation, dermal thickening and hair growth in mice and 
rats (Safer et al., 2001).  These results somewhat differed from what was 
expected so a subsequent study by Safer et al. sought to distinguished between 
systemic and local T3 effects on the skin, by using intraperitoneal and topical 
administration, respectively.  After two weeks, mice that had received T3 
intraperitoneally had 58% less hair per millimeter (mm) than controls, but 
epidermal and dermal thickness did not change significantly in these mice.  
However, mice that were administered T3 topically had 160% more hairs/mm 
than controls.  In addition, the epidermis was 62% thicker and the dermis was 
145% thicker with topical T3 when compared to controls (Safer et al., 2003).  The 
study also showed that T3 action can cause both keratinocyte and fibroblast 
proliferation when cultured independently, but that keratinocyte proliferation is not 
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observed when co-cultured with fibroblasts (Safer et al., 2003).  A couple of 
different hypotheses have been offered to explain the varying effects of systemic 
and topical T3 administration.  For one, it’s possible that tissue deiodinases, 
especially D3, protect against elevated levels of T3 by inactivating T3 to rT3, 
thereby preventing it from causing dermal or epidermal thickening.  Likewise, in 
vivo skin proliferation may not occur if systemic T3 is causing the release of 
proliferative inhibiting factors (Safer et al., 2003).  
Based on these findings, researchers began to wonder whether T3 may 
have a role in wound healing.  Thus, the effects of topical administration of T3 
were evaluated more specifically in wound healing.  10 mm incisions were made 
on the dorsal skin of mice and treated with 150 Nano grams (ng) of T3 cream 
everyday afterwards.  Wounds were analyzed four days later and it was found 
that mice receiving T3 treatment had 53% greater wound closure than mice that 
were not receiving T3 treatment, therefore, demonstrating a positive role for TH 
in wound healing (Safer et al., 2005). 
Since this experiment, genomic-level studies have investigated how T3 
might act at the molecule level.  Keratins are TH responsive genes because T3 
directly regulates these genes via their nuclear receptors (Ohtsuki et al., 1992).  
Keratins are intermediate filament proteins within epithelial cells and represent 
30% of the protein in the epidermis (Safer et al., 2004).  Keratins K6a, K16 and 
K17 have been directly implicated in wound repair, and therefore provide a 
possible mechanism for TH action.  Although TH causes the proliferation of these 
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keratin genes, positive TRE have yet to be identified in keratin genes (Ohtsuki et 
al., 1992).   
Overall, there has been limited research dedicated to molecular action of 
TH in skin.  One recent study by Tarameshloo et al. confirmed the proliferative 
effect of TH during wound healing.  Researchers made small incisions in the 
dorsal skin of rats and topically administered a thyroid hormone cream (TC) 
everyday.  Histological sections of the wound sites were analyzed four days later.  
Tarameshloo et al. concluded that the mean number of fibroblasts and blood 
vessels were greater in rats receiving TC compared to controls.  In addition, the 
mean thickness of the epithelium was larger in rats receiving TC treatment 
compared to controls (Tarameshloo et al., 2012).  
Although T3 positively affects wound healing, the mechanism of its action 
is generally unknown.  Since wound healing involves such a large and variable 
number of growth factors, cells, and proteins, and since TRs have been identified 
in a number of components in the skin, it may be challenging to determine its 
course of action.  However, certain proteins are essential to normal wound 
healing, thus it is possible that THs may exert their influence by increasing 
expression of these proteins either directly or indirectly.  The β1 integrin family of 
proteins is essential in wound healing and therefore was investigated for its 
potential as a target for TH action. 
 Integrins are a family of heterodimeric transmembrane receptor proteins.  
There are 24 known combinations of heterodimers that are derived from 18 
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different α subunits and 8 different β subunits, all of which are encoded by their 
own gene (Wolff & Johnson, 2009).  Integrins are important in cell adhesion, 
proliferation, apoptosis, gene expression, phosphorylation and differentiation.  
They are present in almost all cell types and facilitate communication between 
the extracellular and intracellular environments.  Integrins are expressed on both 
keratinocytes and fibroblasts.  Within the epidermis, they are responsible for 
maintaining the epithelial barrier and connecting keratinocytes to the basement 
membrane of the epidermis (Grenache et al., 2007).  These attachments are 
important in wound healing since a specific keratinocyte deletion of β1 integrins 
results in blister formation at the barrier between the dermis and epidermis 
(Brakebusch et al., 2000). 
Integrin heterodimers α1β1, α2β1, α3β1, α10β1, α11β1 have been 
identified as collagen receptors and are needed to maintain the structural 
integrity of the skin.  The expression of β1 integrins on fibroblasts enables 
binding to bind type 1 collagen and fibronectin, two important elements of the 
extracellular matrix (ECM) (Liu et al., 2010b).  The integrin-β1 protein is also 
crucial for dermal homeostasis because without it, skin is much thinner than 
normal (Liu & Leask, 2012).  Furthermore, when fibroblasts are incubated with an 
antibody for integrin-β1, adhesion between the fibroblasts and the ECM is 
reduced.  This confirms the specific role of integrin-β1 in cell adhesion between 
fibroblasts and the ECM (Shi-Wen et al., 2007).   
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Recent studies have highlighted the importance of integrin-β1 in wound 
healing.  The expression of integrin-β1 was analyzed in lesions of patients with 
scleroderma (SSc), an autoimmune connective tissue disorder that is 
characterized by skin fibrosis and hardening (Imboden, Hellmann, & Stone, 
2006).  Overexpression of integrin-β1 was reported in these lesions, suggesting 
that the integrin-β1 protein may play a role in fibrogenesis in vivo (Shi-Wen et al., 
2007).  A subsequent study conducted by Liu and colleagues induced skin 
fibrosis by injecting bleomycin subcutaneously into two types of mice: normal 
mice and mice with a conditional KO for integrin-β1.  They observed that normal 
mice developed skin fibrosis while mutant mice with the conditional KO for 
integrin-β1 did not (Liu et al., 2009).  Integrin-β1 is therefore required for skin 
fibrosis and could likely play an important role during the remodeling phase of 
wound healing. 
 Further studies have addressed the role of integrin-β1 in wound healing 
more directly.  Mice with a specific deletion of integrin-β1 revealed a delay in 
cutaneous repair.  These mice had less granulation tissue and the production of 
the ECM was reduced.  In addition, fibroblasts extracted from these mice also 
displayed reduced expression of connective tissue growth factor (CTGF) and 
collagen type 1.  Fibroblasts migrated more slowly, had reduced proliferation and 
demonstrated impaired differentiation into myofibroblasts.  Unlike the wildtype 
form, fibroblasts with a specific deletion of integrin-β1 also had less α-SMA, and 
therefore did not have the ability to generate contractile forces as strongly as 
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wildtype cells (Liu et al., 2010a).  Overall, fibroblasts attach, migrate and remodel 
the ECM, however, these interactions are mediated by the integrin receptor 
proteins located on the surface of the cell.  Since we know that the topical 
application of TH increases dermal thickness, it is possible that TH acts by 
increasing the expression of integrin-β1 by stimulating fibrogenesis in wound 
repair.  
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SPECIFIC AIMS 
Wound healing disorders affect approximately 3 to 6 million Americans 
every year.  In these patients, wounds may take months or even years to heal 
and are usually painful and debilitating, and may significantly impact one’s quality 
of life.  In extreme cases, unclosed wounds may result in amputation.  These 
wound-healing disorders are common in the elderly and diabetics patients, but 
may also be impacted by cancer, smoking, nutrition, stress and obesity (Guo & 
DiPietro, 2010).   
Up until now, wound treatment is highly variable and often unsuccessful.  
One common treatment method approved by Food and Drug Administration 
(FDA) is the topical application of growth factors, such as PDGF.  With this in 
mind, TH was investigated to determine whether it may be a useful topical agent 
for wound healing.  It was found that the topical administration of TH increases 
epidermal, dermal thickness and increases the rate of wound closure (Safer, 
2011).  In addition, the number of blood vessel and fibroblasts are increased at 
the site of injury if topical TH is applied (Tarameshloo et al., 2012). This evidence 
strongly supports a clinical application for TH in wound healing disorders. 
Although TH stimulates wound healing, its mechanism of action is 
unknown.  The wound healing process is very complex and involves several 
different proteins, however, a special role for the integrin-β1 family of proteins 
has been identified.  Integrin-β1 has been demonstrated to promote fibrogenesis 
and cutaneous wound repair.  Thus, a plausible mode of TH action may be to 
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stimulate the expression of the integrin-β1 family of proteins directly or indirectly.  
To test this hypothesis, dermal fibroblasts were dosed with TH overnight and 
protein levels of integrin-β1 were subsequently measured to determine whether 
there any changes resulted in the protein expression of integrin-β1, thereby 
providing a possible molecular target for TH action in wound healing.   
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MATERIALS AND METHODS 
 
CELL CULTURING 
 Dermal fibroblasts were cultured from samples of human foreskin.  The 
fibroblasts were plated with growth media containing Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco), fetal bovine serum (FBS) (Life Technologies) and 
penicillin and streptomycin.  Growth media (DMEM, FBS, Antiobiotic) was 
replaced every three days and dermal fibroblasts were grown in the incubator at 
37°C until cells were confluent.   
CELL PASSING 
 Growth media was removed from the confluent fibroblast stock plate using 
a sterile glass pipette attached to a vacuum.  3 milliliters (mL) of 
ethylenediaminetetra acetic acid (EDTA) were added.  The petri dish was mixed 
gently for 15 seconds and EDTA was removed.  3mL of trypsin (Sigma) was 
added to the stock plate and placed back in the incubator for 10 minutes.  The 
Petri dish was checked under the microscope to ensure cells had detached from 
the pate.  3mL of growth media (DMEM, FBS, Antibiotic) was added to neutralize 
trypsin.  A 10mL pipette was used to dislodge cells from the plate by pipetting the 
cells and solution up and down 3 times.  The solution was removed from the petri 
dish using the 10mL pipette and transferred to a 14 mL centrifuge tube.  Solution 
was centrifuged for 5 minutes.  The supernatant was then removed using a 
sterile pipette and vacuum.  The remaining pellet was re-suspended with 3.75mL 
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of growth media (DMEM, FBS, Antibiotic).  4 petri dishes were prepared by 
adding 9mL of growth media (DMEM, FBS, Antibiotic) to each pate.  1mL of 
pellet solution was added to one of the petri dishes containing growth media.  
This transfer was repeated twice more with two more plates.  The remaining 
0.75mL of pellet-containing solution was added to a separate petri dish 
containing 9mL of media (DMEM, FBS, Antibiotic) and was labeled as the stock 
plate.  All four plates were placed in the incubator overnight.   
DOSING 
 Growth media was removed from all three experimental plates.  3mL of 
phosphate buffered saline (PBS) (Pierce, 28372) was added to each plate, mixed 
for 5 seconds and removed using glass pipette and vacuum.  This step was 
repeated twice more.  PBS is made by dissolving one pouch of BupH PBS Pack 
into 500mL of deionized water.  10mL of DMEM was added to each experimental 
plate along with a fourth plate to create the T3 stock solution (ICN 
Pharmaceuticals).  10µL of 10-3 T3 stock solution was added to the stock plate to 
make a 10-6 T3 solution.  1000µL of 10-6 T3 stock solution was added to the first 
experimental plate to dose fibroblasts with a 10-7 T3 solution.  100µL of 10-6 T3 
stock solution was added to the second experimental plate to dose fibroblasts 
with a 10-8 T3 solution.  10µL of 10-6 T3 stock solution was added to the third 
experimental plate to dose fibroblasts with a 10-9 T3 solution.  The fourth 
experimental did not receive any T3 solution and was left as a control.  100µL of 
double-stripped serum (DSS) was added to each experimental plate including the 
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dosed and control fibroblasts.  Double stripped serum was made by combining 
500mL of FBS, with 25g of resin (Bio-Rad) and 15g of activated charcoal 
(Sigma). Experimental plates of fibroblasts were placed in the incubator 
overnight.     
CELL LYSIS 
 3mL of EDTA was added to each experimental plate.  Each plate was 
mixed gently for 15 seconds and all solution was removed with a glass pipette 
and vacuum.  3mL of trypsin was added to each plate and then placed in the 
incubator for 10 minutes.  The Petri dish was checked under the microscope to 
ensure cells had detached from the pate.  3mL of growth media (DMEM, FBS) 
was added to each plate to neutralize trypsin.  Each plate was tilted and solution 
was scraped to the bottom of petri dish using a plastic scraper.  A 10mL pipette 
was used to dislodge cells from each plate by pipetting the cells and solution up 
and down 3 times.  The solution was removed from each petri dish and placed in 
individually labeled 14 mL centrifuge tubes using the 10mL pipette.  The samples 
were spun for 5 minutes.   
The supernatant was removed from each sample using a sterile glass 
pipette and a vacuum.  250µL of cold lysis buffer was added to each sample.  
The lysis buffer was made by dissolving one tablet of protease inhibitor cocktail 
(Complete Mini) into 10mL of Ripa buffer (Sigma). The samples containing lysis 
buffer were placed on ice for 15 minutes.  The solutions were then transferred to 
Eppendorf tubes and centrifuged for 10 minutes at 4°C and 1300 rotations per 
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minute (RPMs).  Supernatent was then collected using a micropipette and 
transferred to new Eppendoft tubes.  Final protein samples were stored at -80°C 
until used for Western Blotting.   
 
WESTERN BLOTTING 
BUFFERS 
 Running buffer and transfer buffer solutions were made for the Western 
Blotting protocol.  The running buffer was made by adding 50mL of 20X 
sodiumdodecyl sulphate (SDS) Running buffer (Invitrogen) to 950mL of 
deionized dihydrogen oxide (dH2O).  The 10x transfer buffer was made by mixing 
30.3 g of Tri Base (Fisher Scientific), 144 g Glycine (Fisher Scientific) and 1L of 
dH2O.  The 1x Transfer Buffer solution was made by combining 200mL of 
methanol, 100mL of 10x transfer buffer and 700 mL of dH2O.  Both solutions 
were stored in the refrigerator until needed.   
GEL ELECTROPHORESIS 
 Protein samples were defrosted.  5µL of Sample Reducing Agent 
(Invitrogen) was added to three separate Eppendorf tubes.  Then 12.5µL of 
lithium dodecyl sulfate (LDS) Sample Buffer (Invitrogen) and 26µL of each 
protein sample was also added to each tube.  Solutions were placed in a 70°C 
water bath for ten minutes.  Combs and white tape from Bis-Tris Gels (Invitrogen) 
were removed and placed in the Bio-Rad Mini-Gel Box Electrotransfer Kit.  
Approximately 900mL of the runner buffer was added to the middle chamber of 
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the Mini-Gel Box.  500µL of antioxidant (Invitrogen) was also added to the middle 
chamber.  The gel was loaded with 15µL of See Blue Reference Ladder 
(Invitrogen) in the well furthest to the left, and 15µL of each sample was added to 
wells in the particular order that is marked in the Western Blots.  The gel was run 
at 176 V for approximately 40 minutes.   
MEMBRANE TRANSFER 
 The gel was separated from the gel cassette and proteins were 
transferred to a Novex LC 2001 Nitrocellulose 0.45 um membrane.  One piece of 
filter paper and one piece of sponge was placed on both sides of the 
nitrocellulose membrane and the gel.  The 5 layers were inserted into a transfer 
cassette and placed in the transfer box.  Approximately 950 mL of transfer buffer 
was added to the box.  The transfer was run at 220mA for 50 minutes.   
MEMBRANE BLOCKING AND ANTIBODY INCUBATION 
 The membrane was removed from the cassette and the orientation was 
labeled.  The membrane was covered in 5% milk blotting solution for one hour.  
10% milk blotting solution was made from adding 5mL of powdered milk and 
50mL of 1x Tris Buffered Saline with Tween (TBST) (Cell Signaling), and then 
further diluted to 5%.  The blotting solution was removed and membrane was 
incubated with primary antibody solution for β-actin (Cell Signaling) and integrin-
β1 (Cell Signaling).  The β-actin and integrin-β1 antibodies were both diluted to 
1:1000 in 1% milk solution.  Nitrocellulose membranes were incubated in primary 
antibody solutions overnight.   
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 The following day, the primary antibody solution was removed.  The 
membrane was covered in 1x TBST and agitated for 5 minutes and then 
removed.  This step was repeated twice more.  The membrane was then covered 
in secondary antibody solution for anti-mouse to detect β-actin (Cell Signaling) 
and anti-rabbit to detect integrin-β1 (Sigma).  The anti-mouse antibody dilution 
was 1:2000 and the anti-rat antibody dilution was 1:5000.  The membrane was 
incubated for one hour at room temperature.   
MEMBRANE EXPOSURE 
The secondary antibody solution was removed.  The membrane was covered in 
1x TBST and agitated for 5 minutes and then removed.  This step was repeated 
twice more.  Enhanced chemiluminescence (ECL) solution was added in two 
parts by first adding 2mL of Reagent A (luminol) and 2mL of Reagent B (an 
enhancer) (Novex).  The membrane was exposed for approximately ten minutes.  
Excess ECL solution was removed from the membrane and then placed in a 
plastic covering inside the developing cassette.  Inside the dark room, a film (GE 
Healthcare) was placed over the membrane and exposed for 2 minute and 6 
minute intervals. 
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RESULTS 
 Several Western Blots were analyzed to determine whether TH had an 
effect on the expression of integrin-β1.  β-actin was used as an internal control in 
the experiment because it is constitutively expressed in fibroblasts and therefore 
is assumed to be unchanged with the administration of TH.  Therefore, the 
protein of interest was compared to baseline levels β-actin to determine whether 
the expression of integrin-β1 changed in response to TH.  The results are 
summarized in Figures 3-5.   
Figure 3: Expression of Integrin-β1. Integrin-β1 expression is extremely scarce when 
fibroblasts are not dosed with TH.  Thus, it appears that the expression of integrin-β1 is 
dependent on the presence of TH.  The expression of integrin-β1 is fairly consistent over varying 
doses of TH and the dose-dependent relationship is likely to fall below concentrations of 10-9 of 
TH.   
 35 
  
 
Figure 4: Expression of β-actin and integrin-β1. The comparison of protein levels between β-
actin and integrin-β1 demonstrates that integrin-β1 remains relatively constant over increasing 
doses of TH, although it is possible that integrin-β1 expression may decrease slightly.     
 
Figure 5: Ratio of Integrin-β1/β-actin.  β-actin expression should remain constant in all 
physiological conditions.  Thus, it can be used as a baseline to calculate the trend in expression 
of integrin-β1 with increasing doses of TH.  Overall, integrin-β1 protein expression remains 
relatively constant over increasing doses of TH, but appears to decrease very slightly. 
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In general, the expression of integrin-β1 appears to be dependent on the 
presence of TH since the expression of integrin-β1 is virtually undetectable in 
fibroblasts that have not been dosed with TH.  Among the varying doses of TH in 
fibroblasts, the expression of integrin-β1 decreases slightly as the concentration 
of TH is increased, although the statistical significance of these observations is 
unknown.  
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DISCUSSION 
 
 Wound healing disorders significantly affect one’s quality of life and have 
costly consequences for the US healthcare system.  As the prevalence of 
diabetes continues to rise, wound-healing disorders are likely to become more 
problematic for both patients and clinicians. The treatments for wound healing 
are extremely variable and the heterogeneity of interventions makes it extremely 
difficult to determine the validity of many treatments.  Nevertheless, the most 
widely used treatments appear to include skin substitutes, negative-pressure 
wound therapy, oxygen, amputations and the topical application of growth factors 
and other ingredients.  Thyroid hormone is among the ingredients that have 
demonstrated a positive role in wound healing via topical application, but the 
specific proteins involved are unknown.  Thus, the involvement of integrin-β1 was 
tested as a potential molecular target for TH action in dermal fibroblasts.     
 The results of the study indicate that in the absence of TH, the expression 
of integrin-β1 is extremely scarce.  This implies a plausible role for TH in wound 
healing because the expression of integrin-β1 in fibroblasts is an important 
component of wound healing and regulates the deposition of the ECM during the 
remodeling stage of wound repair and the overall rate of cutaneous wound 
healing.  The presence of TH may increase the expression of integrin-β1 by 
directly stimulating gene transcription or by indirectly stimulating gene expression 
via another intracellular mechanism.  
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There are several downstream events that may be influenced by 
increases in integrin-β1 protein.  For example, fibroblasts are likely to migrate to 
the site of injury more quickly and efficiently because cell adhesion between 
fibroblasts and the ECM is improved.  This is based on the evidence that mutant 
mice with a conditional KO of integrin-β1 migrate more slowly to the site of injury.  
If fibroblasts are able to reach the site of injury more quickly, then they will be 
able to deposit collagen and fibronectin earlier after tissue injury and improve the 
wound healing process.  In addition, the overexpression of integrin-β1 may also 
stimulate fibroblast proliferation.  This is conceivable because studies have 
shown that wounds treated with topical application of TH have greater number of 
fibroblasts than controls, and conditional KOs of integrin-β1 have impaired 
fibroblast proliferation.  Therefore, increased levels of integrin-β1 may increase 
fibroblast proliferation and cause further deposition of the ECM in the dermal 
layer of the wound.  
The increase in integrin-β1 expression may also influence fibroblast 
differentiation, since the conversion of fibroblasts to myofibroblasts is impaired in 
mice with a conditional KO for integrin-β1.  Therefore, the increase in integrin-β1 
expression may result in a greater number of myofibroblasts, ultimately 
increasing the overall contractile force of the cells in the wound area.  This will 
result in better rates of wound healing and more efficient closure of the wound 
site overall.   
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There are logical explanations for the increase in integrin-β1 expression in 
the presence of TH as it relates to wound healing, however, the slight decrease 
in its expression in response to greater doses of TH is somewhat puzzling.  The 
most likely explanation for this correlation considers the fact the dose-dependent 
relationship between TH and integrin-β1 is probably occurring at TH 
concentrations that are less than 10-9. Since the physiological concentration of 
TH is comparable to the experimental concentrations of TH at 10-9, the 
observations may demonstrate that integrin-β1 is maximally stimulated at these 
physiological concentrations.  Therefore, as the concentration of TH increases to 
greater than physiological concentrations, TH may become toxic to dermal 
fibroblasts and cause a decrease in integrin-β1 expression.  Therefore, future 
studies should include TH doses of 10-10 and 10-11 in order to determine whether 
this is the case.  Other explanations should consider the potential error 
associated with this lab experiment: if the gel was not loaded with identical 
amounts of protein in each well, comparisons between the control and integrin-β1 
may be very difficult to assess and may be prone to error.   
Overall, the large increase in the expression of integrin-β1 in fibroblasts 
dosed with TH establishes a plausible mechanism of TH action in wound healing.  
As the expression of integrin-β1 protein is increased, fibroblast migration, 
proliferation and differentiation may be enhanced.  These events may provide a 
molecular explanation for the changes observed in the dermal thickness as well 
as the increased rates of wound healing in mice treated with the topical 
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application of thyroid hormone in vivo.  In addition, the increase in integrin-β1 
expression may also explain the increase in the number of fibroblasts that are 
found at the site of the wound in rats treated with TH.  Ideally, further research is 
required to determine whether there is a dose-dependent relationship between 
TH and integrin-β1 expression at lower concentrations of TH.  In addition, TH is 
likely to influence the expression of other proteins in the wound healing process 
that should be identified.  As we uncover the molecular targets for TH action, 
better therapeutic solutions for patients who suffer from wound healing disorders 
may become more realistic.  
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